2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2476

Performance of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) Appears to be Better Than Gold Standard Disease Assessment Score (DAS-28 CRP)
Abstract Number: 396

Performance of Disease Activity Measures in Juvenile Spondyloarthritis in a Placebo Controlled Trial with Infliximab
Abstract Number: 419

Performance of Framingham Risk Factor Score in Predicting Cardiovascular Events in Patients with Polymyalgia Rheumatica
Abstract Number: 1291

Performance of Magnetic Resonance Imaging and 18fluoride Sodium Positron Emission Tomography with Computed Tomography to Assess Inflammatory and Structural Abnormalities of the Sacroiliac Joint in Axial Spondyloarthritis
Abstract Number: 698

Performance of Modified Minimal Disease Activity (MDA) in Patients with Peripheral Spondyloarthritis
Abstract Number: 2017

Performance of Modified Rodnan Skin Score in Early Diffuse Cutaneous Scleroderma-Analysis from 4 International Cohorts
Abstract Number: 445

Performance of Promis Measures in a Multi-Ethnic Population-Based Systemic Lupus Erythematosus (SLE) Cohort
Abstract Number: 706

Performance of the ASAS Classification Criteria for Axial and Peripheral Spondyloarthritis – a Systematic Literature Review and Meta-Analysis
Abstract Number: 94

Performance of the Patient Reported Outcomes Measurement Information System (PROMIS) Measure for Physical Function in Early RA
Abstract Number: 2912

Performance of the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 in Systemic Sclerosis -Associated Interstitial Lung Disease (SSc-ILD)
Abstract Number: 2661

Performance of the Proposed ACR-EULAR Criteria for Sjogren’s Syndrome in a Prospective Multidisciplinary Diagnostic Cohort from Daily Clinical Practice
Abstract Number: 2199

Peri-Aortic Adipose Tissue Volume Is Directly Associated with Fat Accumulation in Adjacent Trunk Muscles Independent of Other Fat Depots: The Framingham Study
Abstract Number: 1095

Periarticular Bone Loss in Arthritis Is Induced By Autoantibodies Against Citrullinated Vimentin
Abstract Number: 309

Periarticular Tibial Knee Bone Mineral Density Is Associated with Knee Symptoms
Abstract Number: 875

Pericardial Involvement in Biopsy-Proven Giant-Cell Arteritis (GCA) Patients Detected By CT Angiography (CTA): Prevalence at Diagnosis and Outcome with Glucocorticoid (GC) Treatment

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].